Your browser doesn't support javascript.
loading
Impact of Chemotherapy Delay on Overall Survival for AML with IDH1/2 Mutations: A Study in Adult Chinese Patients.
Wang, Jing-Han; Guo, Qi; Ma, Zhi-Xin; Ma, Qiu-Ling; Yu, Meng-Xia; Yin, Xiu-Feng; Lu, Sha-Sha; Xie, Hong-Qiong; Jiang, Yue-Hong; Shen, Dan; Ma, Li-Ya; Shi, Hui; Yu, Wen-Juan; Lou, Ye-Jiang; Li, Ying; Yang, Min; Xu, Gai-Xiang; Mao, Li-Ping; Li, Jian-Hu; Wang, Huan-Ping; Wang, Dong-Mei; Wei, Ju-Ying; Tong, Hong-Yan; Huang, Jian; Jin, Jie.
Afiliação
  • Wang JH; Department of Hematology & Institute of Hematology, The First Affiliated Hospital, Zhejiang University, Hangzhou, China; Key Laboratory of Hematopoietic Malignancies, Zhejiang Province, Hangzhou, Zhejiang, PR China.
  • Guo Q; Department of Nephrology, The First Affiliated Hospital, Zhejiang University, Hangzhou, China.
  • Ma ZX; Department of Hematology & Institute of Hematology, The First Affiliated Hospital, Zhejiang University, Hangzhou, China.
  • Ma QL; Department of Hematology & Institute of Hematology, The First Affiliated Hospital, Zhejiang University, Hangzhou, China; Key Laboratory of Hematopoietic Malignancies, Zhejiang Province, Hangzhou, Zhejiang, PR China.
  • Yu MX; Department of Hematology & Institute of Hematology, The First Affiliated Hospital, Zhejiang University, Hangzhou, China.
  • Yin XF; Department of Hematology & Institute of Hematology, The First Affiliated Hospital, Zhejiang University, Hangzhou, China.
  • Lu SS; Department of Hematology & Institute of Hematology, The First Affiliated Hospital, Zhejiang University, Hangzhou, China.
  • Xie HQ; Department of Hematology & Institute of Hematology, The First Affiliated Hospital, Zhejiang University, Hangzhou, China.
  • Jiang YH; Department of Hematology & Institute of Hematology, The First Affiliated Hospital, Zhejiang University, Hangzhou, China.
  • Shen D; Department of Hematology & Institute of Hematology, The First Affiliated Hospital, Zhejiang University, Hangzhou, China.
  • Ma LY; Department of Hematology & Institute of Hematology, The First Affiliated Hospital, Zhejiang University, Hangzhou, China.
  • Shi H; Department of Hematology & Institute of Hematology, The First Affiliated Hospital, Zhejiang University, Hangzhou, China.
  • Yu WJ; Department of Hematology & Institute of Hematology, The First Affiliated Hospital, Zhejiang University, Hangzhou, China.
  • Lou YJ; Department of Hematology & Institute of Hematology, The First Affiliated Hospital, Zhejiang University, Hangzhou, China.
  • Li Y; Department of Hematology & Institute of Hematology, The First Affiliated Hospital, Zhejiang University, Hangzhou, China.
  • Yang M; Department of Hematology & Institute of Hematology, The First Affiliated Hospital, Zhejiang University, Hangzhou, China.
  • Xu GX; Department of Hematology & Institute of Hematology, The First Affiliated Hospital, Zhejiang University, Hangzhou, China.
  • Mao LP; Department of Hematology & Institute of Hematology, The First Affiliated Hospital, Zhejiang University, Hangzhou, China.
  • Li JH; Department of Hematology & Institute of Hematology, The First Affiliated Hospital, Zhejiang University, Hangzhou, China.
  • Wang HP; Department of Hematology & Institute of Hematology, The First Affiliated Hospital, Zhejiang University, Hangzhou, China.
  • Wang DM; Department of Hematology & Institute of Hematology, The First Affiliated Hospital, Zhejiang University, Hangzhou, China.
  • Wei JY; Department of Hematology & Institute of Hematology, The First Affiliated Hospital, Zhejiang University, Hangzhou, China.
  • Tong HY; Department of Hematology & Institute of Hematology, The First Affiliated Hospital, Zhejiang University, Hangzhou, China; Key Laboratory of Hematopoietic Malignancies, Zhejiang Province, Hangzhou, Zhejiang, PR China.
  • Huang J; Department of Hematology & Institute of Hematology, The First Affiliated Hospital, Zhejiang University, Hangzhou, China; Key Laboratory of Hematopoietic Malignancies, Zhejiang Province, Hangzhou, Zhejiang, PR China.
  • Jin J; Department of Hematology & Institute of Hematology, The First Affiliated Hospital, Zhejiang University, Hangzhou, China; Key Laboratory of Hematopoietic Malignancies, Zhejiang Province, Hangzhou, Zhejiang, PR China.
PLoS One ; 10(10): e0140622, 2015.
Article em En | MEDLINE | ID: mdl-26466372
Assuntos
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Leucemia Mieloide Aguda / Protocolos de Quimioterapia Combinada Antineoplásica / Isocitrato Desidrogenase / Mutação Tipo de estudo: Diagnostic_studies / Prognostic_studies Limite: Adolescent / Adult / Aged / Aged80 / Female / Humans / Male / Middle aged País/Região como assunto: Asia Idioma: En Revista: PLoS One Assunto da revista: CIENCIA / MEDICINA Ano de publicação: 2015 Tipo de documento: Article
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Leucemia Mieloide Aguda / Protocolos de Quimioterapia Combinada Antineoplásica / Isocitrato Desidrogenase / Mutação Tipo de estudo: Diagnostic_studies / Prognostic_studies Limite: Adolescent / Adult / Aged / Aged80 / Female / Humans / Male / Middle aged País/Região como assunto: Asia Idioma: En Revista: PLoS One Assunto da revista: CIENCIA / MEDICINA Ano de publicação: 2015 Tipo de documento: Article